Provided by Tiger Fintech (Singapore) Pte. Ltd.

Viking Therapeutics

27.94
-0.1500-0.53%
Post-market: 27.960.0200+0.07%19:56 EST
Volume:3.19M
Turnover:88.37M
Market Cap:3.14B
PE:-27.70
High:28.30
Open:28.18
Low:26.97
Close:28.09
Loading ...

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

Dow Jones
·
07 Feb

U.S. RESEARCH ROUNDUP-Altus Power, Amazon, Nevro

Reuters
·
07 Feb

Viking Therapeutics Reports Strong Trials and Financial Health

TIPRANKS
·
07 Feb

Viking Therapeutics Is Maintained at Strong Buy by Raymond James

Dow Jones
·
07 Feb

Viking Therapeutics Reports Q4 2024 Financial Results, Advances VK2735 Trials

GuruFocus.com
·
07 Feb

Stock Track | Viking Therapeutics Plunges Nearly 10% on Q4 Earnings Miss, Lack of Major Obesity Drug Updates

Stock Track
·
06 Feb

Stock Track | Viking Therapeutics Plunges Nearly 10% on Q4 Miss, Lack of Major Pipeline Breakthroughs

Stock Track
·
06 Feb

Viking Therapeutics Shares Down 5.1% After Co Reports Bigger-Than-Expected Q4 Loss

THOMSON REUTERS
·
06 Feb

Viking Therapeutics price target raised to $125 from $122 at Raymond James

TIPRANKS
·
06 Feb

VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%

Zacks
·
06 Feb

Q4 2024 Viking Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
06 Feb

Has the Bubble Burst for Viking Therapeutics Stock?

Motley Fool
·
06 Feb

BUZZ-Viking Therapeutics falls as analysts call updates on obesity drug trial 'incremental'

Reuters
·
06 Feb

Viking Therapeutics Price Target Maintained With a $102.00/Share by HC Wainwright & Co.

Dow Jones
·
06 Feb

Viking Therapeutics: Strategic Advancements and Promising Outlook in Obesity Treatment Market Fuel Buy Recommendation

TIPRANKS
·
06 Feb

Viking Therapeutics Shares Down 8.2% Premarket After Co Reported Bigger-Than-Expected Q4 Loss

THOMSON REUTERS
·
06 Feb